BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 16941647)

  • 1. Distinct fluctuations of ammonia levels during asparaginase therapy for childhood acute leukemia.
    Steiner M; Attarbaschi A; Kastner U; Dworzak M; Haas OA; Gadner H; Mann G
    Pediatr Blood Cancer; 2007 Oct; 49(5):640-2. PubMed ID: 16941647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of dose-reduced Medac L-asparaginase on coagulation in trial ALL-BFM 2000.
    Attarbaschi A; Mann G; Kronberger M; Witt V; Gadner H; Dworzak M
    Klin Padiatr; 2003; 215(6):321-6. PubMed ID: 14677096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
    Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A fluorometric assay for L-asparaginase activity and monitoring of L-asparaginase therapy.
    Ylikangas P; Mononen I
    Anal Biochem; 2000 Apr; 280(1):42-5. PubMed ID: 10805519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Significance of L-asparaginase activity and biochemical parameters evaluation in children with acute lymphoblastic leukemia].
    Pawińska K; Balwierz W; Sztefko K; Czogała M
    Przegl Lek; 2006; 63(1):44-6. PubMed ID: 16892900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.
    Rizzari C; Citterio M; Zucchetti M; Conter V; Chiesa R; Colombini A; Malguzzi S; Silvestri D; D'Incalci M
    Haematologica; 2006 Jan; 91(1):24-31. PubMed ID: 16434367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
    Pession A; Valsecchi MG; Masera G; Kamps WA; Magyarosy E; Rizzari C; van Wering ER; Lo Nigro L; van der Does A; Locatelli F; Basso G; Aricò M
    J Clin Oncol; 2005 Oct; 23(28):7161-7. PubMed ID: 16192600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Research on the pharmacokinetics and pharmacodynamics of L-asparaginase during its treatment of childhood acute lymphoblastic leukemia].
    Chen FX; Cui YQ; Wu ZL; Ye TZ; Lai YH; Zou YW; Lu CY; Guan JM; Wei FG; Zhang H
    Zhonghua Xue Ye Xue Za Zhi; 2005 Feb; 26(2):100-2. PubMed ID: 15921627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transient hyperammonemia due to L-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma.
    Jörck C; Kiess W; Weigel JF; Mütze U; Bierbach U; Beblo S
    Pediatr Hematol Oncol; 2011 Feb; 28(1):3-9. PubMed ID: 20615069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The role of anti L-asparaginase antibody in childhood acute lymphoblastic leukemia].
    Akazai A; Oda M; Nishiuchi R; Horiuchi T; Henmi M; Manki A; Seino Y
    Rinsho Ketsueki; 1996 Feb; 37(2):95-100. PubMed ID: 8852025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.
    Hunault-Berger M; Chevallier P; Delain M; Bulabois CE; Bologna S; Bernard M; Lafon I; Cornillon J; Maakaroun A; Tizon A; Padrazzi B; Ifrah N; Gruel Y;
    Haematologica; 2008 Oct; 93(10):1488-94. PubMed ID: 18728028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of anti-asparaginase antibodies in childhood acute lymphoblastic leukemia.
    Zalewska-Szewczyk B; Andrzejewski W; Bodalski J
    Pediatr Blood Cancer; 2004 Oct; 43(5):600-2. PubMed ID: 15382279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ex vivo production of ammonia predicts L-asparaginase biological activity in children with acute lymphoblastic leukemia.
    Watanabe S; Miyake K; Ogawa C; Matsumoto H; Yoshida K; Hirabayashi S; Hasegawa D; Inoue T; Kizu J; Machida R; Ohara A; Hosoya R; Manabe A
    Int J Hematol; 2009 Oct; 90(3):347-352. PubMed ID: 19768519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.
    Henriksen LT; Nersting J; Raja RA; Frandsen TL; Rosthøj S; Schrøder H; Albertsen BK;
    Br J Haematol; 2014 Jul; 166(2):213-20. PubMed ID: 24702187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unbalanced coagulation-fibrinolysis potential during L-asparaginase therapy in children with acute lymphoblastic leukaemia.
    Semeraro N; Montemurro P; Giordano P; Schettini F; Santoro N; De Mattia D; Giordano D; Conese M; Colucci M
    Thromb Haemost; 1990 Aug; 64(1):38-40. PubMed ID: 2274927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
    Mitchell LG; Andrew M; Hanna K; Abshire T; Halton J; Anderson R; Cherrick I; Desai S; Mahoney D; McCuster P; Wu J; Dahl G; Chait P; de Veber G; Lee KJ; Mikulis D; Ginsberg J; Way C;
    Cancer; 2003 Jan; 97(2):508-16. PubMed ID: 12518376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Preliminary study on the safety and pharmacodynamic action of low dose L-asparaginase].
    Wu ZL; Chen FX; Ye TZ; Lai YH; Cui YQ; Zou YW; Lu CY; Lan SL; Zhong GY; Guan JM; Wei FG; Zhang H
    Zhonghua Xue Ye Xue Za Zhi; 2006 Jan; 27(1):14-6. PubMed ID: 16732932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of ammonia concentration as a diagnostic test in monitoring of the treatment with L-asparaginase in children with acute lymphoblastic leukemia.
    Czogała M; Balwierz W; Sztefko K; Rogatko I
    Biomed Res Int; 2014; 2014():945860. PubMed ID: 25157375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and drug monitoring of L-asparaginase treatment.
    Boos J
    Int J Clin Pharmacol Ther; 1997 Mar; 35(3):96-8. PubMed ID: 9088996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination of l-asparaginase in children treated for acute lymphoblastic leukemia.
    Brueck M; Koerholz D; Nuernberger W; Juergens H; Goebel U; Wahn V
    Dev Pharmacol Ther; 1989; 12(4):200-4. PubMed ID: 2504568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.